Valeant CEO Joe Papa: Increasing revenue, paying down debt 2017 top priorities: 3 key notes

Laval, Canada-based Valeant Pharmaceuticals CEO Joe Papa said the company is focusing on increasing its revenue and paying down debt at the New York City-based RBC investor conference, Reuters reports.

1. Valeant started the year by selling off $2.1 billion in assets.

2. The company has $30.4 billion in lingering debt. Through selling off strategic assets, however, it avoided paying additional interest on a bond.

3. As of Feb. 24, 2017, Valeant shares were trading at $16.24 per share. The company has a 52-week high of $86.50 and a 52-week low of $13.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast